Last updated 2026-07-27
TL;DR
A certificate of analysis (CoA) confirms a compounded sirolimus batch matches its labeled potency, purity, and sterility test results, usually from USP 41 assays. It does not prove the drug works for longevity, does not replace FDA approval, and covers one batch only. Always check the date, batch number, and testing lab, and ask whether sterility and endotoxin results are included, more than potency.
What is a certificate of analysis for sirolimus, exactly?
A certificate of analysis (CoA) is a lab document tied to one specific batch of compounded sirolimus. It reports what an independent or in-house lab found when it tested that batch: the measured amount of active drug versus what the label claims, plus results for purity, identity, and often sterility and endotoxin levels. For a compounded drug, the CoA is the closest thing to proof that what's in the vial matches what's on the label. That matters more for sirolimus than for most drugs, because sirolimus for longevity use is compounded off-label, not dispensed as an FDA-approved product with its own manufacturing oversight chain. The FDA-approved forms of this molecule are Rapamune (oral solution and tablets) for transplant rejection, and Fyarro and Hyftor for specific tumor and skin conditions [1]. None of those approvals cover aging or lifespan extension. Off-label longevity dosing runs entirely on the credibility of the compounding pharmacy and its paperwork, and the CoA is the paperwork. Sirolimus and rapamycin are the same molecule. Rapamycin was the name given to the compound isolated from Streptomyces hygroscopicus on Easter Island (Rapa Nui) in the 1970s; sirolimus is the pharmaceutical name used once it became a drug [2]. You'll see both terms on lab documents interchangeably, and that's normal, not a red flag.
What does a compounded sirolimus CoA actually test for?
A real CoA reports a short list of specific, numbered results, not vague reassurance. For sirolimus, the standard panel usually includes: potency (percent of labeled strength, typically expected in a 90-110% range under USP compounding standards for non-sterile preparations), identity confirmation (usually by HPLC, confirming the molecule present is actually sirolimus and not a similar compound), and purity or related-substance testing (screening for degradation products). If the preparation is sterile (true for injectable forms, less relevant for oral capsules), the CoA should also show sterility testing and bacterial endotoxin testing, both governed under USP General Chapters <71> and <85> respectively [3]. Beyond-use dating, the compounding equivalent of an expiration date, should also appear, generally set according to USP <795> or <797> stability guidance depending on preparation type [3]. What a CoA does not test: it does not test whether sirolimus at the dose you're taking extends human lifespan, reduces frailty, or does anything at all for aging. No lab assay measures that. It only measures whether the compound in the vial is what it claims to be, at the concentration claimed, free of contamination. Potency and purity are necessary but not sufficient. A perfectly pure batch of a drug with no proven human longevity benefit is still a drug with no proven human longevity benefit.
Does a certificate of analysis prove the sirolimus is safe or effective?
No. This is the single most important thing to understand about a CoA, and it's worth saying plainly: a CoA proves batch quality, not clinical benefit. The strongest lifespan data for rapamycin comes from mice, not humans. The National Institute on Aging's Interventions Testing Program (ITP), running since 2004 across three test sites, found that rapamycin extended median lifespan in genetically heterogeneous mice by roughly 9-14% in males and 13-26% in females depending on dose and start age, with effects seen even when treatment began late in life (starting at 20 months) [4]. That is genuinely strong, repeated, peer-reviewed animal data. It is also mice, not people. There is no completed human randomized controlled trial showing rapamycin extends human lifespan or healthspan. The largest human safety signal comes from short trials in older adults looking at immune function markers, not survival, such as the 2014 Novartis-funded trial (mTOR inhibitor RAD001, an everolimus analog) that found improved influenza vaccine response in adults over 65 taking a low dose for 6 weeks [5]. That's an immune biomarker study measured in weeks, not a lifespan trial measured in years. Nobody has run the second kind in humans. A clean CoA on your vial changes none of this. It just tells you the vial itself isn't the problem; the problem is that off-label longevity dosing is still an unproven human intervention regardless of how pure the compound is.
What are the real risks even with a perfect certificate of analysis?
A pristine CoA does not neutralize sirolimus's known pharmacology. This drug is an mTOR inhibitor and immunosuppressant first, approved originally to prevent transplant rejection, and its risk profile follows from that mechanism regardless of the dosing schedule used for longevity purposes. Immunosuppression is the headline risk. Sirolimus's FDA label for Rapamune carries warnings about increased susceptibility to infection at chronic immunosuppressive doses . Longevity protocols use intermittent, lower doses than transplant regimens specifically to try to reduce this risk, but intermittent low-dose use has not been studied for long-term infection risk in otherwise healthy people; the human data simply doesn't exist at that dose and schedule. Mouth ulcers (stomatitis) are one of the most commonly reported side effects in clinical trials of sirolimus, appearing in a meaningful share of transplant patients on the drug . People using off-label longevity protocols report the same thing, often dose-dependent and manageable by adjusting timing, but it's real and common enough to expect, not a rare fluke. Metabolic effects are also documented: sirolimus use is associated with elevated blood lipids (hypertriglyceridemia and hypercholesterolemia) and, in some patients, new-onset hyperglycemia, per the FDA label . This is exactly why periodic blood work matters if you're using this off-label, regardless of how good your CoA looks. None of these risks show up on a certificate of analysis. A CoA can't warn you about a drug's own approved-label side effects; that's what the long-term side effects and contraindications pages are for.
How do you read a sirolimus CoA line by line?
| Batch/lot number | Unique identifier matching your vial's label | Confirms the CoA is for your actual batch, not a template | |
|---|---|---|---|
| Test date | Recent, ideally close to fill date | Old testing on a new batch is a mismatch | |
| Potency result | Percentage of labeled strength (commonly 90-110% per USP compounding tolerance) | Confirms actual drug content | |
| Identity test method | Usually HPLC | Confirms it's sirolimus, not a substitute | |
| Purity/related substances | Percentage of degradation products | Flags a badly stored or aged batch | |
| Sterility (if injectable) | Pass/fail per USP <71> | Contamination risk | |
| Endotoxin level | Units per mL, per USP <85> | Fever/reaction risk if elevated | |
| Beyond-use date | Specific date | Tells you the compounding pharmacy's own stability claim | |
| Testing lab name | Named, ideally third-party independent lab | In-house-only testing is weaker evidence than independent verification | A generic CoA with no batch number, or one that looks identical across multiple orders months apart, is a warning sign. Batches vary. If the numbers never change, someone may be reusing a template rather than testing each run. |
Look for these specific fields; if any are missing, ask why before you trust the batch. | Field | What it should show | Why it matters |
Who actually tests compounded sirolimus, and under what rules?
Compounding pharmacies in the US operate under state pharmacy board licensing and, for many, under USP General Chapters <795> (non-sterile compounding) and <797> (sterile compounding), which are enforceable quality standards incorporated into many state regulations [3]. Some pharmacies also register with the FDA as 503B outsourcing facilities, which subjects them to current Good Manufacturing Practice (cGMP) requirements and FDA inspection, a materially higher bar than a standard 503A compounding pharmacy operating under a patient-specific prescription . This distinction is worth asking about directly. A 503A pharmacy compounds per individual prescription and is regulated primarily at the state level; a 503B outsourcing facility can compound in batches without patient-specific prescriptions and is FDA-registered and inspected . Neither status means the drug is FDA-approved for longevity use; sirolimus's approvals remain limited to Rapamune, Fyarro, and Hyftor for their specific labeled conditions [1]. But 503B status generally means more consistent, more frequently audited testing, which should show up as more rigorous and more frequent CoAs.
What should you ask your prescriber or pharmacy before trusting a CoA?
Ask five things, and expect real answers, not brochure language. First, is the CoA batch-specific or a generic template? Ask to see the batch number on both the vial label and the CoA and confirm they match. Second, who performed the testing: an independent third-party lab, or the compounding pharmacy's own in-house lab? Both are used in practice, but independent testing is generally considered stronger evidence because it removes the incentive conflict of a pharmacy grading its own homework. Third, does the CoA include sterility and endotoxin data, or only potency? This matters most for injectable formulations. Fourth, is the pharmacy a 503A or 503B facility, and is it licensed in your state? You can typically verify pharmacy licensure through your state board of pharmacy's public license lookup tool. Fifth, and separately from the CoA entirely: has your prescriber discussed the actual evidence gap with you? A pharmacy's job is quality control of the compound. It is not their job, and not the CoA's job, to tell you whether off-label longevity dosing is supported by human trial data. It currently isn't, beyond the mouse work and short biomarker studies noted above [4][5]. That conversation belongs with a prescriber reviewing your case, which is the model behind Sirolimus Rx's provider-reviewed process, where a clinician evaluates suitability before any prescription reaches a compounding pharmacy for fulfillment.
How does a CoA compare to FDA drug approval?
| Confirms | Safety and efficacy for a specific approved indication | Batch potency, purity, sterility | |
|---|---|---|---|
| Reviewed by | FDA, based on clinical trial data | Testing lab, batch by batch | |
| Covers longevity use? | No approved indication for aging/lifespan | No, doesn't address use case at all | |
| Applies to | The whole approved product | One specific batch/lot | Understanding this table is the whole point of this article. A great CoA on an off-label longevity vial tells you the compounding was done competently. It tells you nothing about whether the underlying use case, extending human lifespan, is proven. It isn't, yet. For the actual state of human and animal evidence, see results: what the research shows and be skeptical of any before-and-after claims that aren't backed by controlled trial data, because individual anecdotes aren't controlled for anything a CoA or a trial would catch. |
These are not substitutes for each other, and conflating them is the most common mistake buyers make. FDA approval (Rapamune, Fyarro, Hyftor) means the drug went through Phase 1-3 trials for a specific indication, with the FDA reviewing efficacy and safety data before granting approval for that named use [1]. A CoA involves no efficacy review at all. It's a batch quality snapshot, generated by or for the compounding pharmacy, confirming the compound matches its label. No regulatory body reviews a CoA for a decision about whether the drug should be used for a given purpose. | | FDA drug approval | Certificate of analysis |
What should you do with the CoA once you have it?
Keep it. File it next to the order confirmation and lot number, and pull it out again if you ever have an adverse reaction, so your prescriber can rule out a contaminated or mis-dosed batch versus a known side effect of the drug itself. Cross-check the potency number against your intended dose using a proper dosage calculator rather than eyeballing it; small variances in labeled-versus-actual potency matter more at the low, intermittent doses used in longevity protocols than at fixed clinical transplant doses. And treat the CoA as one input among several, not a verdict. Combine it with routine blood work monitoring lipids, glucose, and kidney function, a real conversation about contraindications, and an honest read of the evidence gap. A clean CoA plus no monitoring is still a bad plan.
Frequently asked questions
What is a certificate of analysis in the context of sirolimus?
It's a lab report for one specific compounded batch of sirolimus, showing measured potency versus labeled strength, purity, identity confirmation, and often sterility and endotoxin results. It verifies the compound in the vial matches its label; it does not verify safety or effectiveness for any particular use, including longevity.
Is sirolimus the same as rapamycin?
Yes. Rapamycin is the original name for the compound isolated from soil bacteria on Rapa Nui (Easter Island) in the 1970s; sirolimus is the pharmaceutical name for the same molecule used in FDA-approved products like Rapamune [2]. You'll see both terms used interchangeably on labels and CoAs.
Does a CoA mean the sirolimus is FDA-approved for longevity use?
No. A CoA is a batch-quality document from a compounding pharmacy or lab, unrelated to FDA drug approval. Sirolimus is FDA-approved only as Rapamune, Fyarro, and Hyftor for specific transplant, tumor, and skin conditions, not for aging or lifespan extension [1]. Longevity use is entirely off-label regardless of CoA quality.
What potency range is normal on a sirolimus CoA?
Compounding standards under USP generally allow a tolerance range, commonly around 90-110% of labeled strength for non-sterile preparations, though exact acceptable ranges depend on the specific USP chapter and pharmacy protocol applied [3]. Anything far outside that range, or unreported, should prompt a question to the pharmacy before use.
Can a CoA tell me if sirolimus will extend my lifespan?
No, and no CoA anywhere can, because that isn't what it tests. The strongest lifespan evidence is from the NIA Interventions Testing Program in mice, showing roughly 9-26% median lifespan extension depending on sex and dose [4]. There is no completed human lifespan trial, so no document, including a CoA, can confirm a human longevity effect.
What's the difference between a 503A and 503B compounding pharmacy?
A 503A pharmacy compounds per individual patient prescription and is regulated mainly at the state level. A 503B facility is FDA-registered, can compound in batches, and must follow current Good Manufacturing Practice (cGMP) rules with FDA inspection [7]. Neither status makes sirolimus FDA-approved for longevity use, but 503B generally means more rigorous, more frequent testing.
What are the real risks of off-label sirolimus even with a clean CoA?
Immunosuppression (increased infection risk), mouth ulcers (stomatitis), and metabolic effects like elevated triglycerides, cholesterol, or blood sugar are documented on the FDA label for sirolimus at approved doses [6]. A clean CoA confirms the compound's quality, not that these known drug effects won't occur at your dose.
Does a CoA test for sterility?
Only if it's an injectable formulation and the pharmacy includes that testing, typically per USP General Chapter <71> for sterility and <85> for bacterial endotoxins [3]. Oral capsule CoAs usually focus on potency, identity, and purity instead. Always check which tests are actually listed, not assumed.
How often should a compounding pharmacy test each batch?
Standard practice is batch-specific testing for every production run, not periodic sampling. If a pharmacy provides an identical-looking CoA across multiple separate orders, ask directly whether each batch was tested individually or whether one older report is being reused.
Is there a human trial proving rapamycin extends lifespan?
No completed human randomized controlled trial has shown rapamycin extends human lifespan. The closest human data are short trials on immune biomarkers, such as a 2014 study finding improved vaccine response in older adults on a low mTOR-inhibitor dose over 6 weeks, which measured immune function, not survival [5].
Should I ask my prescriber about the CoA before starting sirolimus?
Yes. Ask whether the compounding pharmacy provides batch-specific CoAs, whether testing is done by an independent lab, and what monitoring (blood work, symptom checks) will accompany your prescription. A provider-reviewed process, like the one behind Sirolimus Rx, is meant to pair prescribing judgment with pharmacy quality documentation rather than leaving you to interpret a CoA alone.
What should I do if my sirolimus CoA is missing information?
Ask the pharmacy for the missing fields before use, specifically the batch number, test date, potency result, and testing lab name. If they can't or won't provide batch-specific documentation, treat that as a legitimate reason to pause and seek a different source rather than assuming it's fine.
Sources
- FDA, Drugs@FDA database entries for Rapamune, Fyarro, and Hyftor: Sirolimus is FDA-approved as Rapamune (transplant rejection), Fyarro, and Hyftor for specific labeled indications, not for aging or lifespan extension
- NIH National Center for Biotechnology Information, PubChem Compound Summary for Sirolimus: Sirolimus and rapamycin refer to the same molecule, originally isolated from Streptomyces hygroscopicus
- United States Pharmacopeia, General Chapters <795>, <797>, <71>, <85>: Compounding potency tolerances, sterility, and endotoxin testing standards are set under specific USP General Chapters
- NIA Interventions Testing Program, published results (Harrison et al., Nature 2009; Miller et al., J Gerontol A 2011/2014): Rapamycin extended median lifespan in genetically heterogeneous mice across NIA ITP cohorts, including when started late in life
- Mannick et al., Science Translational Medicine 2014, 'mTOR inhibition improves immune function in the elderly': A low-dose mTOR inhibitor improved influenza vaccine response in adults over 65 in a 6-week trial measuring immune biomarkers, not lifespan